Related Experiment Video
Updated: Mar 27, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Prevention of HBV reactivation in patients treated with biologic agents
Christos Koutsianas1,2, Konstantinos Thomas1, Dimitrios Vassilopoulos1
1a Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory , National and Kapodistrian University of Athens Medical School, Hippokration General Hospital , Athens , Greece.
Abstract:
Owing to the sensitive equilibrium between the hepatitis B virus (HBV) and the host's immune system in infected and exposed individuals, the immunosuppression caused by biologic treatment has been strongly linked to HBV reactivation (HBVr). HBVr in the setting of biologic therapy is a cause of considerable morbidity, hospitalization, interruption of treatment and mortality. However, recent literature has established that this is a largely preventable problem. Thus, it is essential for clinicians using biologic agents to be aware of HBVr potential and screen all susceptible patients. The risk for HBVr may vary depending on the host's HBV infection status and the potency of immunosuppression. The appropriate pre-emptive antiviral prophylaxis or monitoring for individuals at risk is emphasized in the latest evidence-based guidelines, but a number of unanswered questions remain.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Retrovirus Life Cycles
Hepatitis
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Hypersensitivity Reactions: Cytolytic Reactions

